VolitionRX Limited, a life sciences company focused on making its non-invasive blood tests for cancer as common and easy to use as tests for diabetes and cholesterol, today announced the creation of a Clinical Evaluation Management Committee that will act as a semi-independent advisory board providing guidance on clinical trials and validation strategy for U.S. and European product approval. The committee is comprised of four internal Volition members and three independent external advisors. Plans are for the committee to meet monthly. External members will spend up to three days each month on Volition business.
“As we have had very promising results in internal lab testing on small numbers of samples for our Nucleosomics range of blood-based cancer tests, we are now starting to plan for the clinical trials concurrent with testing larger numbers of samples,” said Cameron Reynolds, President and Chief Executive Officer of Volition in a press statement. “The members of the Clinical Evaluation Management Committee are all experts in their respective fields and will be absolutely instrumental in helping shape our trials strategy to bring our tests to market as expeditiously as possible.”
The four internal candidates are Cameron Reynolds, CEO; Belgian Volition Managing Director Patrick Rousseau; Belgian Volition Chief Scientific Officer Dr. Jake Micallef; and senior scientist Dr. Marielle Herzog.
The three external candidates have impressive backgrounds. Dr. Remy von Frenckell, the chairman, is a medical statistician with over 20 years experience in corporate and academic posts, including work at Bristol Myers Squibb International, USB Pharma and European Organization for Research and Treatment of Cancer (EORTC). Professor Carlos Graux serves as a haematologist and Associate Head of Clinic in the Department of Clinical Hematology at CHU Mont-Godinne (UCL), Yvoir, Belgium as well as coordinator of the biobank. He is an experienced researcher and serves as the principal investigator of clinical trials on acute leukemia and myelodysplastic syndrome. Currently, he is collaborating on research into tumor resistance to chemotherapy. Ludwig Everaert is an expert in the area of clinical trials advising on Phase I, II, III, IV and observational trials. He is currently the General Manager of MPI, Zemst and manages a consultancy business with a specialty in regulatory affairs having authored regulatory affairs documents for over 150 medicines. Mr. Everaert had also served as Scientific Affairs Manager at Faulding Pharmaceuticals in Belgium
For full biographies of the all committee members, please visit the Volition website at www.volitionrx.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment